We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

HELD Hellenic Dynamics Plc

0.0134 (16.75%)
02 Oct 2023 - Closed
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.

Share Name Share Symbol Market Type Share ISIN Share Description
Hellenic Dynamics Plc LSE:HELD London Ordinary Share GB00B3CQW227 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0134 16.75% 0.0934 0.085 0.095 0.09 0.08 0.08 37,091,875 16:45:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Gen Contractor-nonres Bldgs 0.0 -4.9 - - 11.70

Hellenic Dynamics Share Discussion Threads

Showing 701 to 723 of 1775 messages
Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older
cheers oak - '6 Expected cultivation cycles per annum'
about 9 weeks per cycle.

Another new low. All very odd.
From my earlier post wrtmf:

* HELD have been granted one of the largest cultivation licenses in Europe.

* Based in a secure, ex UN facility in Northern Greece.

* Fully funded to first sales, anticipated in late Q2.

* Term sheets already signed with distributors into primary market of Germany.

* Germany with 300K existing patients (2020) with 70% of prescriptions covered by insurance.

* 10.7 tons of medicinal cannabis imports in 2018.

* 20.8 tons of medicinal cannabis imports in 2019.

* 31.5 tons of medicinal cannabis imports in 2020.

* Potential to sign other significant contracts into continental Europe.

* 25 Countries now on stream and open for medicinal cannabis prescription.

* European mkt anticipated to be worth 37 Billion Euros by 2027 (this is twice the size of
the Canadian and North American Markets, combined).

* UK is intended secondary market, with the potential to address the current opioid epidemic (540k patients
currently addicted to prescribed opioids). 26% of uk population suffering from chronic pain.

* Strategically located in Northern Greece to have one of the lowest cost of production anywhere in Europe
(labour, energy, climate all ideal + own water supply).

* 0.06 euros kn/h.

* 0.00 euros water.

* 48 miles from major freight airport to all main European sales destinations.

* The growing site has already received significant investment.

* Expansion to be phased in line with contracts and growing demand. Expansion intended to be
funded through sales.

* Total area of site: 195,506 M2. 3.8km perimeter.

* License and scalability of the site good to 54,000 kg dried flowers per annum.

* As a comparison, CEL's UK facility is good for circa 5000 kg, with the associated inflated
costs of UK energy / production / labour.

* 6 Expected cultivation cycles per annum.

* Intention / aspiration to penetrate UK market via the NHS and compete on quality and

* Growing from clones to ensure product stability.

* Key staff appointed to the Development Team eg Carl Haffner (ex Avida Global). Proven
track record in achieving a large-scale medical cannabis cultivation and extraction
facility in Colombia achieving all necessary certifications including ISO, GACP & EU-GMP.

* We are Main Market, not AIM.

* Strong advisory board, with Hannah Deacon as a key, high-profile advocate.


* Memorandum of Understanding with ELGO-DIMITRA - Institute of Plant Breeding and Genetic Resources of Greece

* Appointment of Katherine Fleming to its Advisory Board. Katherine is currently the President and CEO of the J. Paul Getty Trust, the international cultural and philanthropic institution, overseeing its 1,500 employees and US$8.5 billion endowment fund.

consider how many advisors over the protracted fca process took fees in shares over £s?
is it 9 weeks for a production cycle from cutting to cropping/drying? or was it 9 cycles per year?
about 2 weeks to get equipment installation complete or they could miss q2 first sale/income?

Seems like mr.10mill sell has endless stock??? Any idea the seller???
Is that a 20M buy to start the week with?

We're moving into an important quarter for the company.

Any near term milestones/catalysts? We should be hearing about
Could be a delayed trade here. But the buy quotes, even for a small quantity, are already at full ask again. Odd. May uptick again if any support arrives this afternoon.

I think yesterday's appointment was a significant and reassuring development.

The Greek government obviously hold K.F. in the highest regard; very good therefore to have her on our Advisory Board.

Once again, I would like to see some buying from within the company at these levels. A c.10M valuation is very low.

Nothing to suggest anything to the contrary thus far, comedy. That is their plan.

Confirmation of cash flows and perhaps other supply agreements into Europe and we should move much higher imho.


hoping we get first crop next quarter.
Bought another mill plus. Most of portfolio all in here now. Gl all holders
Very pleased.

The story is building.

Hopefully an operations update this quarter and perhaps even the inking of further supply agreements.

In the meantime, are the shares on sale? Time will tell if accumulation at these levels was prudent. I have only added at these prices for the medium term.


First a five year research agreement with a Greek government department.....and today what seems to be a very high quality appointment. Interesting that HELD, even at these early stages, is able to attract such interest:

Hellenic Dynamics PLC Appointment of Katherine Fleming to Advisory Board
27/03/2023 7:00am
UK Regulatory (RNS & others)

Hellenic Dynamics (LSE:HELD)
Intraday Stock Chart

Monday 27 March 2023

Click Here for more Hellenic Dynamics Charts.

RNS Number : 2334U

Hellenic Dynamics PLC

27 March 2023

27 March 2023

Hellenic Dynamics plc

("Hellenic Dynamics" or the "Company")

Appointment of Katherine Fleming to Advisory Board

London, 27 March 2023: Hellenic Dynamics plc (LSE: HELD) a medical cannabis cultivation company, is pleased to announce the appointment of Katherine Fleming to its Advisory Board. Katherine is currently the President and CEO of the J. Paul Getty Trust, the international cultural and philanthropic institution, overseeing its 1,500 employees and US$8.5 billion endowment fund.

Katherine previously held the position of Provost and Professor of History of New York University, the largest private university in the United States by enrolment, where she is also the Alexander S. Onassis Chair of Hellenic Studies. As Provost, she oversaw the University's global academic strategy and was responsible for budgetary allocation. Past international appointments have included serving as President of the Board of the University of Piraeus, Greece and as associate member of the faculty of the École Normale Supérieure in Paris, France.

Katherine holds a number of honours including being named to the French Légion d'Honneur and being decorated by the Greek Government as a commander in the Order of Beneficence. In 2016 Katherine was recognized for her contributions to Greek culture by being granted honorary Greek citizenship.

Katherine will assist Hellenic Dynamics both domestically in Greece with her strong and well-established relationships, as well as on the international stage as it aims to be the dominant supplier of THC medical cannabis products in Europe.

Hellenic Dynamics is a medical cannabis cultivator specifically focused on the cultivation and supply of tetrahydrocannabinol (" THC") dominant strains of medical cannabis flowers destined for the rapidly growing medical cannabis markets across Europe. In December 2022, Hellenic Dynamics became the first medical cannabis cultivator to list on the London Stock Exchange's main market for listed securities.

Davinder Rai, CEO of Hellenic Dynamics, commented:

"We are honoured to have Katherine join our Advisory Board and I personally look forward to working with her. Katherine brings a huge breadth of experience that will benefit Hellenic both domestically in Greece and in wider Europe."

Katherine Fleming, commented:

"I'm delighted to join Hellenic Dynamics, which connects two worlds about which I care deeply: patients for whom medical cannabis can improve their quality of life and outcomes, and Greece - a country with massive potential for being the leader in the European medical cannabis cultivation space."

Seems a decent appointment
Now just need the tick up:-)
A collaboration with a partner who is in the public sector is the encouragement. It suggests long term local governmental support for HELD's ops. The Greek government has, I believe already stopped import of medicinal cannabis, favouring instead to supply home-grown for the domestic population. I've already said that I think HELD will be the likely supplier of choice domestically. Working with an established government body on the research and protection side, with the necessary knowledge bank, seems like a good choice in respect of the long-term viability of the company. It probably also means they will have access into a leading skill-set and established genetic research infrastructure at an eventual price (probably royalties or a profit-share) infinitely less that trying to do this work alone, or even outsourcing it.

CEL propose to do similar I believe, but it would be interesting to see how they are going about it and how taxing their approach will be to their ongoing cost base.

Edited below.
lol just few of us here
i topped up with 3mill just now:)
Excellent RNS....I had been hoping to hear more about the genetic banking side of the business....and here it is. Perhaps the most significant aspect of this update is exactly with whom HELD will be working - positive in that they themselves are PUBLIC sector and working under Greek Ministry of Agriculture, Development and Food.


You say "Looks like they want to change to generics and produce a super plant and patent the rights if I am reading it right - aiming to be the only supplier of a super plant"

No change. The plan was always to work with genetics, as I previously highlighted on this thread and as referenced in the Company prospectus.

Over time, it will enable the company to tailor certain strains which prove efficacious for certain indications, including specific pain indications. I didn't know exactly who the collaboration would be with till this morning. As the company points out, there may be the potential for Patent protection for anything they develop in this collaboration.

Good update.

Looks like they want to change to generics and produce a super plant and patent the rights if I am reading it right - aiming to be the only supplier of a super plant
Really interesting - and positive - news this morning

Please keep your posts to HELD.
We don't mind the odd post related to other shares but you need to keep it to a minimum.

Chat Pages: Latest  35  34  33  32  31  30  29  28  27  26  25  24  Older
Your Recent History
Hellenic D..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20231003 01:52:11